Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T21:03:59.364Z.
Calculation as of: 2026-10-06T21:03:59.364Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 64b8b41d6b5635a3630374b271ba93e5d0b13f976b61d7cdc588ead55f2777d6
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Market Cap
$2.13M
EV/EBITDA Ratio
N/A
TTM Avg
10388992794.84x
3Y Avg
12435877641.77x
5Y Avg
12435877641.77x
Market Cap
$2.32M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.37M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$2.38M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.88M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Vivos Therapeutics, Inc. (VVOS) | $2.14M | N/A | N/A | N/A | N/A |
| GeoVax Labs, Inc. (GOVX)vs › | $2.13M | N/A | 10388992794.84x | 12435877641.77x | 12435877641.77x |
| Creative Medical Technology Holdings, Inc. (CELZ)vs › | $2.32M | N/A | N/A | N/A | N/A |
| FibroBiologics, Inc. Common Stock (FBLG)vs › | $2.37M | N/A | N/A | N/A | N/A |
| Onconetix, Inc. (ONCO)vs › | $2.37M | N/A | N/A | N/A | N/A |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH)vs › | $2.38M | N/A | N/A | N/A | N/A |
| Moleculin Biotech, Inc. (MBRX)vs › | $2.38M | N/A | N/A | N/A | N/A |
| Autonomix Medical, Inc. (AMIX)vs › | $1.88M | N/A | N/A | N/A | N/A |
| TransCode Therapeutics, Inc. (RNAZ)vs › | $1.88M | N/A | N/A | N/A | N/A |
| Tenon Medical, Inc. (TNON)vs › | $1.84M | N/A | N/A | N/A | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
